Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FBRX Forte Biosciences	$9.79 +1.9%	$11.34	$4.11 ▼ $28.68	$63.27M	2.91	43,914 shs	44,097 shs
IGMS IGM Biosciences	$1.30 -0.8%	$1.27	$0.92 ▼ $22.50	$78.75M	0.6	569,854 shs	146,642 shs
LEXX Lexaria Bioscience	$0.88 +2.9%	$0.94	$0.79 ▼ $4.38	$16.63M	0.79	200,890 shs	66,185 shs
VNRX VolitionRx	$0.62 -2.7%	$0.68	$0.40 ▼ $0.94	$64.78M	1.26	196,095 shs	41,933 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FBRX Forte Biosciences	+1.87%	-15.82%	-29.11%	+54.91%	+46,070.53%
IGMS IGM Biosciences	-0.76%	+3.17%	-4.06%	+11.11%	-85.14%
LEXX Lexaria Bioscience	+2.90%	-2.23%	-2.23%	-18.98%	-76.60%
VNRX VolitionRx	-2.66%	-14.69%	-21.14%	+19.76%	-2.09%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FBRX Forte Biosciences	3.1294 of 5 stars	3.5	5.0	0.0	0.0	1.7	0.6
IGMS IGM Biosciences	4.2357 of 5 stars	3.0	3.0	4.6	2.7	3.3	0.6
LEXX Lexaria Bioscience	2.8516 of 5 stars	3.5	2.0	0.0	2.3	3.3	0.6
VNRX VolitionRx	1.4828 of 5 stars	3.5	0.0	0.0	0.0	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FBRX Forte Biosciences	3.00	Buy	$61.00	523.08% Upside
IGMS IGM Biosciences	1.90	Reduce	$5.50	323.08% Upside
LEXX Lexaria Bioscience	3.00	Buy	$4.00	357.14% Upside
VNRX VolitionRx	3.00	Buy	$3.50	461.80% Upside

Current Analyst Ratings Breakdown

Latest LEXX, FBRX, VNRX, and IGMS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/29/2025	LEXX Lexaria Bioscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $4.00
7/17/2025	VNRX VolitionRx	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
7/9/2025	VNRX VolitionRx	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
7/1/2025	LEXX Lexaria Bioscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$7.00 ➝ $5.00
6/24/2025	FBRX Forte Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$61.00
6/10/2025	VNRX VolitionRx	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$3.00

(Data available from 8/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	$8.21 per share	N/A
IGMS IGM Biosciences	$2.68M	29.16	N/A	N/A	$0.82 per share	1.59
LEXX Lexaria Bioscience	$460K	37.21	N/A	N/A	$0.48 per share	1.82
VNRX VolitionRx	$1.31M	49.51	N/A	N/A	($0.11) per share	-5.66

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FBRX Forte Biosciences	-$35.48M	-$16.29	N/A	N/A	N/A	N/A	-149.15%	-114.25%	8/13/2025 (Estimated)
IGMS IGM Biosciences	-$195.79M	-$0.90	N/A	N/A	N/A	-36.81%	-93.35%	-24.15%	8/13/2025 (Estimated)
LEXX Lexaria Bioscience	-$5.80M	-$0.67	N/A	N/A	N/A	-1,849.19%	-157.22%	-133.69%	N/A
VNRX VolitionRx	-$35.32M	-$0.27	N/A	∞	N/A	-2,321.14%	N/A	-163.39%	N/A

Latest LEXX, FBRX, VNRX, and IGMS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	FBRX Forte Biosciences	-$1.21	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q2 2025	IGMS IGM Biosciences	-$0.12	N/A	N/A	N/A	$0.40 million	N/A
7/31/2025	Q2 2025	IGMS IGM Biosciences	-$0.30	$1.58	+$1.88	$1.58	$3.20 million	$143.62 million
7/14/2025	Q3 2025	LEXX Lexaria Bioscience	-$0.15	-$0.21	-$0.06	-$0.21	$0.17 million	$0.17 million
5/15/2025	Q1 2025	FBRX Forte Biosciences	-$0.89	-$1.37	-$0.48	-$1.37	N/A	N/A
5/13/2025	Q1 2025	IGMS IGM Biosciences	-$0.41	-$0.86	-$0.45	-$0.86	$4.25 million	$0.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	N/A
IGMS IGM Biosciences	N/A	N/A	N/A	N/A	N/A
LEXX Lexaria Bioscience	N/A	N/A	N/A	N/A	N/A
VNRX VolitionRx	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FBRX Forte Biosciences	N/A	5.22	5.22
IGMS IGM Biosciences	N/A	17.66	17.66
LEXX Lexaria Bioscience	N/A	3.90	3.90
VNRX VolitionRx	N/A	0.22	0.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FBRX Forte Biosciences	77.63%
IGMS IGM Biosciences	42.79%
LEXX Lexaria Bioscience	13.06%
VNRX VolitionRx	8.09%

Insider Ownership

Company	Insider Ownership
FBRX Forte Biosciences	5.90%
IGMS IGM Biosciences	57.00%
LEXX Lexaria Bioscience	26.40%
VNRX VolitionRx	10.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FBRX Forte Biosciences	5	6.58 million	6.20 million	Optionable
IGMS IGM Biosciences	190	60.12 million	25.85 million	Optionable
LEXX Lexaria Bioscience	7	19.56 million	14.40 million	Not Optionable
VNRX VolitionRx	80	103.98 million	80.80 million	Optionable

LEXX, FBRX, VNRX, and IGMS Headlines

Recent News About These Companies

VolitionRx Announces Pricing of $1.2 Million Registered Direct Offering

August 4 at 4:01 PM | prnewswire.com

VolitionRx (NYSE:VNRX) Given "Buy" Rating at D. Boral Capital

July 17, 2025 | marketbeat.com

Nu.Q® Discover Expands Global Adoption and Epigenetic Innovation

July 16, 2025 | prnewswire.com

VolitionRx Limited (VNRX) - Yahoo Finance

July 11, 2025 | nz.finance.yahoo.com

Volition Announces Groundbreaking Lateral Flow Test for Point-of-Care Quantification of Nucleosomes

July 8, 2025 | prnewswire.com

Volition Announces MARS Consortium Clinical Study Suggests Nu.Q® H3.1. Concentrations are Closely Associated with Sepsis and Organ Failure

June 12, 2025 | prnewswire.com

Jones Trading Initiates Coverage of VolitionRx (VNRX) with Buy Recommendation

June 11, 2025 | msn.com

VolitionRx director Guy Innes buys $10,772 in common stock

June 5, 2025 | investing.com

Insider Buying: VolitionRx Limited (NYSE:VNRX) Director Buys 20,000 Shares of Stock

June 5, 2025 | insidertrades.com

Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties

June 4, 2025 | prnewswire.com

VolitionRX shares hold as Benchmark maintains rating

May 21, 2025 | uk.investing.com

VolitionRx Limited (AMEX:VNRX) Q1 2025 Earnings Call Transcript

May 20, 2025 | msn.com

Insider Buying: VolitionRx Limited (NYSE:VNRX) Insider Acquires 50,000 Shares of Stock

May 20, 2025 | insidertrades.com

VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats

May 19, 2025 | prnewswire.com

VolitionRX aims for cash flow neutrality in 2025 as human diagnostics licensing advances

May 16, 2025 | msn.com

VolitionRX Limited (VNRX) Q1 2025 Earnings Call Transcript

May 16, 2025 | seekingalpha.com

VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update

May 15, 2025 | prnewswire.com

VolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update

May 12, 2025 | prnewswire.com

VolitionRX Limited: Outlines broad strategy to become the 'NETs company' worldwide through licensing and updates progress of Nu.Q® NETs test adoption

May 7, 2025 | prnewswire.com

VolitionRX Limited: Revolutionizing the diagnosis and monitoring of life-altering diseases for both humans and animals in multi-billion dollar markets

April 29, 2025 | prnewswire.com

VolitionRx enters new sales agreement, terminates old one

April 24, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LEXX, FBRX, VNRX, and IGMS Company Descriptions

Forte Biosciences NASDAQ:FBRX

$9.79 +0.18 (+1.87%)

Closing price 08/4/2025 04:00 PM Eastern

Extended Trading

$8.50 -1.29 (-13.18%)

As of 04:00 AM Eastern

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

IGM Biosciences NASDAQ:IGMS

$1.30 -0.01 (-0.76%)

Closing price 08/4/2025 04:00 PM Eastern

Extended Trading

$1.30 +0.00 (+0.38%)

As of 04:00 AM Eastern

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

Lexaria Bioscience NASDAQ:LEXX

$0.88 +0.02 (+2.90%)

Closing price 08/4/2025 04:00 PM Eastern

Extended Trading

$0.88 +0.00 (+0.11%)

As of 04:18 AM Eastern

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

VolitionRx NYSE:VNRX

$0.62 -0.02 (-2.66%)

Closing price 08/4/2025 04:00 PM Eastern

Extended Trading

$0.62 -0.01 (-1.28%)

As of 04:00 AM Eastern

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time